ERα36 as a Potential Therapeutic Target for Tamoxifen-Resistant Breast Cancer Cell Line Through EGFR/ERK Signaling Pathway

BACKGROUND: Acquired tamoxifen resistance is one of the major barriers to the successful treatment of breast cancer. Recently, overexpression of ERα36 was demonstrated to be a potential mechanism for the generation of acquired tamoxifen resistance. This study aims to evaluate the possibility of ERα3...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Guangliang, Zhang, Jing, Xu, Zhenzhen, Li, Zhongqi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6969677/
https://www.ncbi.nlm.nih.gov/pubmed/32021441
http://dx.doi.org/10.2147/CMAR.S226410

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6969677/
https://www.ncbi.nlm.nih.gov/pubmed/32021441
http://dx.doi.org/10.2147/CMAR.S226410

Ejemplares similares